PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2066982
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2066982
The in vitro toxicology testing market is projected to reach USD 20.97 billion by 2031, growing from an estimated USD 12.69 billion in 2026, at a CAGR of 10.6% during the forecast period. Growth is being driven by increasing use of cell-based assays, 3D culture models, organoids, organ-on-chip systems, high-content screening, automation, and AI-enabled predictive toxicology for early-stage compound screening and safety profiling.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offering, Product, Type, Method, End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
The market is further supported by rising pharmaceutical and biotechnology R&D spending, demand for faster and more human-relevant toxicity prediction, outsourcing to CROs, and regulatory momentum to reduce animal testing while improving preclinical decision-making.

"The products segment accounted for a larger share than the services segment in 2025."
By offering, the products segment accounted for the largest share in the global in vitro toxicology testing market. The products segment led the market because in vitro toxicology workflows depend heavily on recurring product consumption, including assay kits, reagents, cell culture media, sera, buffers, microplates, detection substrates, reference standards, and validated cell models. Unlike services, these products are repeatedly required across every cytotoxicity, genotoxicity, organ toxicity, dermal, ocular, and mechanistic toxicity study.
"North America dominated the in vitro toxicology testing market in 2025."
North America dominated the in vitro toxicology testing market in 2025, primarily due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, well-funded academic research centers, and early adoption of non-animal safety testing technologies across the US and Canada. The region has high demand for cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and mechanistic toxicity testing during drug discovery, preclinical development, cosmetics safety assessment, chemical evaluation, and medical device biocompatibility testing. The US also has a mature ecosystem of assay kit suppliers, cell model providers, organ-on-chip companies, high-content screening platforms, and predictive toxicology software developers, supporting broad commercialization of in vitro toxicology products and services. Regulatory modernization initiatives encouraging alternative methods to animal testing further support adoption.
This research report categorizes the in vitro toxicology testing market by offering {Products [Reagents & Consumables (Cell Lines & Primary Cells, Culture Reagents, Media & Consumables, 3D Models and Tissue Systems, Other Reagents & Consumables), Assay Kits (Cytotoxicity Assay, Genotoxicity Assay, Organ-Specific Toxicity Assay, Other Assays), Equipment (Detection, Imaging & Analytical Systems (Imaging Systems, Detection Instruments, Other Instruments), Liquid Handling & Automation Systems, Other Equipment), Software & Informatics, and Services; Product - By Toxicity End Point (Organ Toxicity Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity and Skin Irritation, Corrosion and Sensitization, Oxidative Stress and Mechanistic Toxicity, Other Toxicity Endpoints and Tests); Product - By Technology (Cell Culture Technologies, High-Throughput and High-Content Technologies, Omics Technologies, Organotypic and Microphysiological Based Technologies, Other Technologies); Product - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Product - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Cros, Academic And Research Institutes, Other End Users); Service- By Type (Toxicology Testing Service, Biological Model And Assay Development Services, Imaging And Analytical Toxicology Services, Data Analysis, Bioinformatics, And Predictive Toxicology); Service - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Service - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Academic And Research Institutes, Other End Users).
The report's scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the in vitro toxicology testing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the in vitro toxicology testing market.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in vitro toxicology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.